12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SMT 19969: Phase I data

A double-blind, placebo-controlled Phase I trial in 56 healthy male volunteers showed that single doses of SMT 19969 and twice-daily doses of SMT 19969 for 10 days were well tolerated. Additionally,...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >